CLIFF Stock Chart & Stats
$0.15
$0.05(46.95%)
At close: 4:00 PM EDT
$0.15
$0.05(46.95%)
Day’s Range― - ―
52-Week Range$0.07 - $0.17
Previous CloseN/A
Volume356.00
Average Volume (3M)100.00
Market Cap
$26.52M
Enterprise Value-$12.77
Total Cash (Recent Filing)$49.83M
Total Debt (Recent Filing)$4.32M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding267,525,360
10 Day Avg. Volume0
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.32
Price to Sales (P/S)0.86
P/FCF Ratio-45.71
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Cell-Banking Revenue ModelLong-term storage contracts can create recurring revenue beyond the initial collection and processing fee. This model may support customer retention and revenue visibility over multiple years, provided service quality and trust are maintained.
Conservative Balance SheetVery low leverage reduces solvency risk and interest-related pressure, giving Cordlife more flexibility to fund operations and address business challenges. The sizable equity base provides a financial buffer while management works toward restoring profitability.
Losses Have ModeratedA solid gross margin and narrower losses suggest some stabilization in the operating model. If sustained, improved cost control could provide a foundation for eventual earnings recovery, although the company has not yet demonstrated durable profitability.
Bears Say
Persistent Net LossesOngoing losses show that current revenue and gross profit are insufficient to cover operating costs. Continued deficits can erode equity and restrict investment capacity, making a sustained turnaround in earnings essential to long-term financial strength.
Negative Operating And Free Cash FlowThe business is not currently funding itself through operations, increasing reliance on existing liquidity or external financing. Persistent negative free cash flow could gradually weaken the balance sheet and limit investment in laboratories, compliance, and growth.
Weak Revenue TrajectoryModest growth from a depressed base indicates limited near-term top-line momentum and does not yet demonstrate a return to historical scale. Weak revenue recovery can constrain operating leverage, prolong losses, and make fixed laboratory and storage costs harder to absorb.
Cordlife Group News
CLIFF FAQ
What was Cordlife Group Limited’s price range in the past 12 months?
Cordlife Group Limited lowest stock price was $0.07 and its highest was $0.17 in the past 12 months.
What is Cordlife Group Limited’s market cap?
Cordlife Group Limited’s market cap is $26.52M.
When is Cordlife Group Limited’s upcoming earnings report date?
Cordlife Group Limited’s upcoming earnings report date is Nov 06, 2026 which is in 70 days.
How were Cordlife Group Limited’s earnings last quarter?
Cordlife Group Limited released its earnings results on Aug 13, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cordlife Group Limited overvalued?
According to Wall Street analysts Cordlife Group Limited’s price is currently Overvalued.
Does Cordlife Group Limited pay dividends?
Cordlife Group Limited pays a Annually dividend of $0.006 which represents an annual dividend yield of N/A. See more information on Cordlife Group Limited dividends here
What is Cordlife Group Limited’s EPS estimate?
Cordlife Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cordlife Group Limited have?
Cordlife Group Limited has 267,525,360 shares outstanding.
What happened to Cordlife Group Limited’s price movement after its last earnings report?
Cordlife Group Limited reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cordlife Group Limited?
Currently, no hedge funds are holding shares in CLIFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cordlife Group Limited
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its operations are structured into two distinct divisions: Banking and Diagnostics. The Banking division is responsible for the collection, processing, storage, and analysis of vital biological samples such as cord blood, cord lining, and various tissue samples. Meanwhile, the Diagnostics division furnishes an array of diagnostic tests, encompassing genetic and metabolic screenings for newborns, pediatric vision and hearing assessments, allergen testing for children, and genetic evaluations for talent identification. Beyond these core services, Cordlife also engages in corneal lenticule banking, gut microbiome storage, and offers lifestyle-focused genetic screening for adults. The company further provides "Moms Up," a mobile application designed to supply parenting information and resources pertinent to health, wellness, and lifestyle needs. Completing its diverse portfolio, Cordlife offers medical laboratory services, marketing support, property investment, alongside specialized consulting and research and development in the medical and pharmaceutical sectors.
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―
Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors